tirzepatide controindicazioni Nuovo farmaco per l'obesità: la Food and Drug Administration e l'Mhra inglese autorizzano (Eli Lilly) Mounjaro, il farmaco contro l'obesità
Description
According to the same meta-analysis , diarrhea may be more common than constipation with Zepbound
Both drugs share the same GI side effect class: nausea, diarrhea, constipation, and vomiting
In laboratory research, it is studied for its role in incretin signaling , glucoselipid metabolism , and energy balance regulation
The side effect profiles are similar between the two, with GI symptoms being the most common for both
At RxPros, we believe every patient deserves care tailored to their unique needs
